None
Conditions
Interventions
Remimazolam Group:Induction phase: remimazolam 0.2 mg/kg + sufentanil 0.5 µg/kg + cisatracurium 0.15 mg/kg.
Maintenance phase: remimazolam 1 mg/(kg·h) + remifentanil 0.2 µg/(kg·h).
Propofol group:Induction phase: propofol 2 mg/kg + sufentanil 0.5 µg/kg + cisatracurium 0.15 mg/kg.
Maintenance phase: propofol 6 mg/(kg·h) + remifentanil 0.2 µg/(kg·h).
Sponsors
Ordos Central Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients scheduled to undergo elective spinal canal decompression, nucleus pulposus removal, or discectomy at the Central Hospital of Ordos City 2. ASA class I–III, able to tolerate general anesthesia 3. No cognitive impairment before surgery, able to cooperate with the experiment 4. Informed consent obtained, voluntarily participating in the study 5. No preoperative anxiety, depression, or insomnia affecting surgical outcomes 6. BMI 17.5–28
Exclusion criteria
Exclusion criteria: 1. Individuals allergic to benzodiazepines 2. Those with severe central nervous system diseases who cannot cooperate to complete the preoperative assessment 3. Individuals with severe atrioventricular block, sick sinus syndrome, or sinus bradycardia (<50 beats/min) 4. Emergency surgery 5. Severe liver or kidney dysfunction 6. Intraoperative blood loss exceeding 1000 ml
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative sleep quality;postoperative recovery quality ; | — |
Secondary
| Measure | Time frame |
|---|---|
| hemodynamic indicators;pain score;analgesic use;Postoperative nausea and vomiting incidence; | — |
Countries
China
Contacts
Public ContactYang Junling
Ordos Central Hospital
Outcome results
None listed